文献速递皮肤肿瘤

Mohs显微描记手术治疗甲单位黑色素瘤的技术与结局

Nail unit melanoma treated with Mohs micrographic surgery: Technique, local recurrence rate, and surgical outcomes.
PubMed 文献 · J Am Acad Dermatol · 2025-01-21

基于2008—2023年前瞻性数据库,69例经活检证实的甲单位黑色素瘤接受Mohs显微描记手术联合黑色素瘤抗原识别T细胞-1(MART-1)免疫组化染色。平均随访38.2个月,局部复发1例(1/69,1.4%);亚临床扩散(>1个Mohs分期)38例(55.1%);为清除肿瘤而截肢仅5例(7.2%),但因骨广泛暴露需截肢重建33例(47.8%)。

要点

  • Mohs显微描记手术联合MART-1染色治疗甲单位黑色素瘤局部复发率低。
  • 亚临床扩散常见,多数病例需超过1个Mohs分期才能清除肿瘤。
  • 为清除肿瘤而截肢少见,但骨广泛暴露的缺损常需截肢重建。

核心结论

  • Mohs显微描记手术联合MART-1免疫组化染色治疗甲单位黑色素瘤可获得较低的局部复发率。
  • 为获得阴性切缘而截肢并不常需要,但为重建骨广泛暴露的Mohs缺损,截肢可能是必要或可取的。

研究设计与样本

  • 单中心前瞻性维护数据库(2008—2023年)纳入的经活检证实的甲单位黑色素瘤病例系列。
  • 共69例甲单位黑色素瘤,其中原位黑色素瘤51例(73.9%)、侵袭性黑色素瘤18例(26.1%),侵袭性者平均Breslow厚度1.07 mm(范围0.2—5.4 mm)。
  • 主要结局为局部复发率,次要结局包括亚临床扩散率和截肢性 versus 重建性截肢率。

主要发现

  • 平均随访38.2个月期间发生局部复发1例(1/69,1.4%)。
  • 亚临床扩散(>1个Mohs分期)38例(38/69,55.1%)。
  • 为清除黑色素瘤而截肢5例(5/69,7.2%)。
  • 因骨广泛暴露而于不同水平截肢以重建缺损33例(33/69,47.8%)。

临床怎么用

  • 甲单位黑色素瘤可采用Mohs显微描记手术联合MART-1免疫组化染色进行保指(趾)手术。
  • 应预期亚临床扩散常见,需预留多个Mohs分期。
  • 切缘阴性后,若缺损伴骨广泛暴露,可考虑截肢性重建。

局限性

  • 单中心队列研究。
  • 缺乏患者报告结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nail unit melanoma (NUM) is increasingly treated with digit-sparing surgery, but few published case series describe Mohs micrographic surgery (MMS) for NUM. OBJECTIVE: To describe the surgical technique, local recurrence rates, and reconstruction method for a large series of NUM treated with MMS using melanoma antigen recognized by T cells-1 immunostaining. METHODS: Biopsy-proven NUM treated with MMS-melanoma antigen recognized by T cells-1 were identified from a prospectively maintained database (2008-2023). Primary outcome was local recurrence rate. Secondary outcomes included rate of subclinical spread and rate of ablative versus reconstructive amputation. RESULTS: Sixty-nine NUM were identified, including 51 melanomas in situ (73.9%) and 18 invasive melanomas (26.1%) with mean Breslow thickness of 1.07 mm (range 0.2-5.4 mm). One local recurrence (1/69, 1.4%) occurred during a mean follow-up time of 38.2 months. Subclinical spread (>1 Mohs stage) was common (38/69, 55.1%). Amputation was rarely necessary to clear the melanoma (5/69, 7.2%), but amputation at different levels was performed to reconstruct 33 cases (33/69, 47.8%) with extensive exposed bone. LIMITATIONS: Single center cohort and lack of patient-reported outcomes. CONCLUSION: MMS treats NUM with low local recurrence rates. Amputation is rarely necessary to obtain clear tumor margins, but it may be necessary or desirable to reconstruct MMS defects with extensive exposed bone.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Valdes Morales KL, Frankel D, Trifoi MD, et al. Nail unit melanoma treated with Mohs micrographic surgery: Technique, local recurrence rate, and surgical outcomes. J Am Acad Dermatol. 2025. PMID: 39848587. doi:10.1016/j.jaad.2024.11.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。